



CURRICULUM VITAE

Steven T. Forman, MD, FACC, FSCAI, RVT

Joined Los Alamitos Cardiovascular as partner in 1999

Managing Partner since 2005

5300 Katella Avenue, Los Alamitos, CA 90720

p: (562) 430-7533 | f: (562) 430-8055 | website: <http://www.losalcardio.com>

<p>Specialties:</p>	<p>Cardiovascular Diseases, Interventional Cardiology, Endovascular Diseases, Venous and Lymphatic Medicine</p>
<p>Board Certifications:</p>	<ul style="list-style-type: none"> • Certified in Venous and Lymphatic Medicine American Board of Venous and Lymphatic Medicine (ABVLM) 2012 • Certified in Interventional Cardiology American Board of Internal Medicine 1999 (Recertification 2009) • Certified in Cardiovascular Disease American Board of Internal Medicine 1997 (Recertification 2017) <hr/> <ul style="list-style-type: none"> • Expert Reviewer The Medical Board of California August 2014 – Present
<p>Additional Certifications:</p>	<ul style="list-style-type: none"> • GCP Certified July 2010 CITI Collaborative Institutional Training Initiative
<p>Research Experience:</p>	<ul style="list-style-type: none"> • AEGIS: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome. Sub-Investigator 2019 Sponsor: CSL Behring LLC NCT03473223: https://clinicaltrials.gov/ct2/show/NCT03473223

- **COVET** : Comparison of Oral anticoagulants for extended Venous Thromboembolism (COVET). It is a randomized, open label, active comparator to determine whether the direct oral anticoagulant apixaban and rivaroxaban are safer than warfarin (fewer bleeding complications) and still as effective as warfarin (no increase in recurrent blood clots).
Principal Investigator | 2018 – Present
Sponsor : Patient-Centered Outcomes Research Institute (PCORI)
NCT03196349: <https://clinicaltrials.gov/ct2/show/NCT03196349>
- **NODE 301**: Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia.
Sub-Investigator | 2019
Sponsor: Milestone Pharmaceuticals Inc.
NCT03464019: <https://clinicaltrials.gov/ct2/show/NCT03464019>
- **NODE 302**: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (Extension of NODE-301).
Sub-Investigator | 2019
Sponsor: Milestone Pharmaceuticals Inc.
NCT03635996: <https://clinicaltrials.gov/ct2/show/NCT03635996>
- **PARADISE MI**: A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction.
Sub-Investigator | 2018 – Present
Sponsor: Novartis
NCT02924727: <https://clinicaltrials.gov/ct2/show/NCT02924727>
- **PEA-VALVE**: Phono- and Electrocardiogram Assisted Detection of Valvular Disease. This is data collection of recorded heart sounds + ECGs using Eko Duo and Eko Core devices to further refine and validate algorithms using de-identified diagnosis confirmed by gold-standard echocardiograms.
Principal Investigator | 2018 – Present
Sponsor: Eko Devices
- **GALACTIC-HF**: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
Principal Investigator | 2017 – Present

Sponsor: Amgen

NCT02929329: <https://clinicaltrials.gov/ct2/show/NCT02929329>

- **PROVE-HF:** A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.

Sub-Investigator | 2017 – 2019

Sponsor: Novartis

NCT02887183: <https://clinicaltrials.gov/ct2/show/NCT02887183>

- **Barostim Therapy for Heart Failure (BeAT-HF):** The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.

Principal Investigator | 2016 – Present

Sponsor: CVRx, Inc.

NCT02627196: <https://clinicaltrials.gov/show/NCT02627196>

- **MLHFQ Study:** Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.

Principal Investigator | 2016 – 2017

Sponsor: Gilead/ICON

- **THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS):** A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).

Sub-Investigator | 2015 – Present

Sponsor: AstraZeneca

NCT01991795: <https://clinicaltrials.gov/show/NCT01991795>

- Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).

Sub-Investigator | 2015 – 2016

Sponsor: Amgen, Evidera

- **DECLARE-TIMI 58 Dapagliflozin Effect on Cardiovascular Events:**
 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
 Principal Investigator | 2013 – 2018
 Sponsor: AstraZeneca
 NCT01730534 | <http://clinicaltrials.gov/ct2/show/NCT01730534>
- **ODYSSEY EFC11570:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
 Sub-Investigator | 2013 – 2017
 Sponsor: Sanofi
 NCT01663402 | <http://clinicaltrials.gov/ct2/show/NCT01663402>
- **SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.**
 Sub-Investigator | 2013 – 2017
 Sponsor: Yale University School of Medicine/NIH
 NCT01755052 | <http://clinicaltrials.gov/ct2/show/NCT01755052>
- **RivaroxAFL3003:** An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
 Principal Investigator | 2013 – 2014
 Sponsor: Janssen Scientific Affairs/Johnson & Johnson
- **Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.**
 Principal Investigator | 2013
 Sponsor: Tasly Pharmaceuticals
 NCT0169580 | <http://clinicaltrials.gov/ct2/show/NCT0169580>
- **Cardiovascular Inflammation Reduction Trial (CIRT):** Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
 Principal Investigator | 2013 – 2018

Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women's Hospital/National Heart Lung and Blood Institute
NCT01594333 | <http://clinicaltrials.gov/ct2/show/NCT01594333>

- **User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.**
Principal Investigator | 2012
Sponsor: Alere San Diego
- **Mission® PT Coagulation Monitoring System Clinical Study.**
Sub-Investigator | 2012
Sponsor: ACON Laboratories, INC.
- **The “BRIDGE” Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.**
Principal Investigator | 2012 – 2015
Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
NCT00786474 | <http://clinicaltrials.gov/ct2/show/NCT00786474>
- **GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.**
Principal Investigator | 2012 – Present
Sponsor: Boehringer Ingelheim
NCT01468701 | <http://clinicaltrials.gov/ct2/show/NCT01468701>
- **California State Elective Percutaneous Coronary Intervention Pilot Program**
Principal Investigator | 2010 – 2014
- **BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.**
Sub-Investigator | 2010 – 2012
Sponsor: St. Jude Medical Center
NCT01062126 | <http://clinicaltrials.gov/ct2/show/NCT01062126>
- **The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.**
Principal Investigator | 2010 – 2014
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
NCT01174550 | <http://clinicaltrials.gov/ct2/show/record/NCT01174550>

- **ORBIT-AF I and II:** Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Principal Investigator | 2010 – 2017
Sponsor: Janssen Scientific Affairs, LLC
Collaborator: Duke Clinical Research
NCT01165710 | <http://clinicaltrials.gov/ct2/show/NCT01165710>
NCT01701817 | <http://clinicaltrials.gov/ct2/show/NCT01701817>
- **RATE:** Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
Sub-Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00837798 | <http://clinicaltrials.gov/ct2/show/NCT00837798>
- **FREEDOM:** A Frequent Optimization Study the Quick Opt™ Method.
Sub-Investigator | 2008 – 2010
Sponsor: St. Jude Medical Center
NCT00418314 | <http://clinicaltrials.gov/ct2/show/NCT00418314>
- **ENGAGE:** Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).
Principal Investigator | 2009 – 2015
Sponsor: Daiichi Sankyo Pharma Development
NCT00781391 | <http://clinicaltrials.gov/ct2/show/record/NCT00781391>
- Phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of Dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV Risk in patients hospitalized for an acute coronary syndrome (ACS) when treatment is initiated within 1 week after an ACS (Dal-ACUTE).
Principal Investigator | 2008 – 2012
Sponsor: F. Hoffmann-La Roche Ltd., Hoffmann-La Roche, Inc. , Roche Global Development.
NCT01323153 | <http://clinicaltrials.gov/ct2/show/NCT01323153>
- Multi-center, randomized, controlled study to investigate the safety and tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in treating iron deficiency anemia in subjects who are not dialysis dependent.
Principal Investigator | 2007 – 2009

	<p>Sponsor: Luitpold Pharmaceuticals, Inc. NCT00704028 http://clinicaltrials.gov/ct2/show/NCT00704028</p> <ul style="list-style-type: none"> Systolic and diastolic myocardial dysfunction during endotoxemia in pigs. Proctor: Roy D Goldfarb, Phd 1989 – 1991 Department of Physiology, Albany Medical College
<p>Current Hospital Appointments:</p>	<ul style="list-style-type: none"> Los Alamitos Medical Center 3751 Katella Avenue Los Alamitos, California 90720 MemorialCare Health System Long Beach Memorial Medical Center 2801 Atlantic Avenue Long Beach, California 90801 Lakewood Regional Medical Center 3700 South Street Lakewood, California 90712
<p>Committees:</p>	<p><i>Los Alamitos Medical Center</i></p> <ul style="list-style-type: none"> Chairman, Board of Governors, January 2018 – December 2019 Director of Cardiac Catheterization Lab, Effective March 2014 Chief of Staff, January 2014 – December 2015 Chairman of Elective PCI Pilot Program, June 2010 – 2014 Vice Chief of Staff, Medical Executive Committee, January 2012 – December 2013 Secretary/Treasurer, Medical Executive Committee, January 2010 – December 2011 Chief of Medicine, January 2007 – December 2010 Chairman of Allied Health Committee, January 2006 – December 2006 Member, Medical Executive Committee, January 2006 – Present Member, Myocardial Infarction Quality Assurance Committee, January 2001 – Present Member, Cardiovascular Quality Assurance Committee, January 2000 – Present <p><i>State of California</i> Member, AOC (Advisory Oversight Committee) for the Elective PCI (Percutaneous Coronary Interventions) Pilot Program for the State of California, June 2010 – 2014</p>

Professional Societies:	<ul style="list-style-type: none"> • American College of Phlebology (RVT) Member • American College of Cardiology (FACC) Fellow • American College of Physicians (FACP) Member • Society for Cardiovascular Angiography and Intervention Member
Academic Appointments:	<ul style="list-style-type: none"> • Volunteer Faculty Department of Medicine/Division of Cardiology University of California , Irvine (UCI) November 2011 – Present • Instructor in Medicine Department of Medicine The New York Hospital /Cornell University Medical Center June 1996 – June 1998
Work History:	<ul style="list-style-type: none"> • Los Alamitos Cardiovascular Los Alamitos, California 1999 – Present • Cardiology Associates of North Jersey 1030 Clifton Avenue Clifton, New Jersey 07013 July 1998 – August 1999 • Urgent Care Physician Memorial Sloan Kettering Cancer Center New York, New York July 1994 – June 1996
Previous Hospital Appointments:	<ul style="list-style-type: none"> • General Hospital of Passaic 350 Boulevard Passaic, New Jersey 07055 July 1998 – August 1999 • Saint Mary’s Hospital 211 Pennington Avenue Passaic, New Jersey 07055 July 1998 – August 1999

	<ul style="list-style-type: none"> • Saint Joseph’s Hospital and Medical Center 703 Main Street Passaic, New Jersey 07055 July 1998 – August 1999 • Chilton Memorial Hospital 97 West Parkway Pomptom Plains, New Jersey 07444 July 1998 – August 1999 • Passaic Beth Israel Hospital 70 Parker Avenue Passaic, New Jersey 07055 July 1998 – August 1999
Publications:	<ul style="list-style-type: none"> • Shaknovich A, Forman ST, Parikh M, Deutsch E, Bergman G, McCaffery T, Newman GC, Tarazona N and Sanborn T. “Novel distal occluder washout methods for prevention of no-reflow during stenting of saphenous vein grafts.” <i>Catheter Cardiovascular Intervention</i>. 1999 Aug: 47(4): 397 – 403. • Marshall ES, Raichlen JS, Forman S, Heyrich GP, Keen WD, Weitz HH. “Adenosine radionuclide perfusion imaging in the preoperative evaluation of patients undergoing peripheral vascular surgery.” <i>American Journal of Cardiology</i>. 1995 Oct 15: 76(11): 817 – 821.
Education:	<ul style="list-style-type: none"> • Interventional Cardiology Fellowship The New York Hospital – Cornell University Medical Center The Division of Cardiology New York, New York July 1997 – June 1998 • Cardiovascular Diseases Fellowship The New York Hospital – Cornell University Medical Center New York, New York July 1994 – June 1997 • Internal Medicine Internship and Residency Thomas Jefferson University Hospital Department of Medicine Philadelphia, Pennsylvania July 1991 – June 1994

- **Medical Education**
Albany Medical College
Albany, New York
MD, May 1991
- **Undergraduate Education**
The Johns Hopkins University
Baltimore, Maryland
Bachelor of Arts in Natural Science, May 1987